BLUE are three of the most promising stocks on my watchlist to buy right now. These three companies have very different businesses, but each one has catalysts coming that could fuel future growth and make them winning investments worth buying now.
AMZN may get the headlines, but it's not the only company transforming retail through e-commerce. Shopify makes its money through monthly subscriptions that increase when retailers upgrade to get greater functionality, but transaction processing is its fastest-growing business. While Shopify already works with thousands of retailers, the potential to continue growing sales, and eventually turn a profit, is big.
According to the U. Microsoft' s Kinect has used this kind of gesture control to enhance the user experience for years, and the incorporation of next-generation 3D-sensing technologies could provide a better user experience for smartphone and tablet users, too. Until now, incorporating this technology into small devices has been hamstrung by battery-draining energy consumption, but Lumentum's on the cusp of changing that.
Recently, the company told investors it's scored a big order that will begin delivery in the third quarter and said demand for 3D sensing will add "meaningful revenue in our next fiscal year. Lumentum hasn't said what company placed this order, but it's confident that this part of its business is going to grow quickly.
Therefore, rapid growth could prove to be very profit friendly. CELG are making on bb, an entirely new approach to fighting multiple myeloma. The approach involves removing patient T-cells, reengineering them using a neutered HIV-1 virus to find B-cell maturation antigen BMCA , a protein expressed by multiple myeloma cells, and reinserting these "smart" cells back into the patient to find and destroy this cancer. The high response rate is particularly exciting because patients in the trial were heavily pre-treated, averaging seven prior lines of therapy each.
Admittedly, bb's results were from a small, early-stage trial, so a lot more research is needed before we know for sure it's effective and safe. Its dominance in the indication suggests it could turn bb into a blockbuster, and bluebird bio could share equally in that success if it exercises an option to co-commercialize bb Given the potential to disrupt multiple myeloma treatment, and its relationship with Celgene, this upstart could be one of the most interesting stories in clinical-stage biotech.
LinkedIn is owned by Microsoft. His clients may have positions in the companies mentioned. The Motley Fool has a disclosure policy. Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In , Todd founded E. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Skip to main content The Motley Fool Fool.
Stock Advisor Flagship service. Rule Breakers High-growth stocks. Income Investor Dividend stocks. Hidden Gems Small-cap stocks. Inside Value Undervalued stocks. View all Motley Fool Services.
Learn How to Invest. Jun 7, at 8:More...